Categories: News

Commonwealth Informatics Helps Life Science Companies and Regulatory Agencies Improve Drug Safety

WALTHAM, Mass., March 22, 2021 /PRNewswire/ — Commonwealth Informatics, an independently-operated subsidiary of Genpact, and leading technology and services company with industry expertise in medical product safety and public health surveillance, today announced the latest release of its Commonwealth Vigilance Workbench (CVW), an innovative cloud-based solution that leverages artificial intelligence and advanced analytics to help life sciences companies and government regulatory agencies improve drug safety through end-to-end signal detection and management.

Commonwealth, in collaboration with its clients, which include four of the top ten pharmaceutical companies, is creating the industry standard for signal detection and management to identify drug adverse effects more quickly and efficiently. Two of the largest global pharmaceutical companies have gone live with CVW’s current release, which helps generate and assess evidence from individual case safety reports, clinical trial data sets, electronic health records, and other information sources.

“Combatting COVID-19 has underscored the critical need for fast and efficient signal detection and management to improve drug safety, and a cloud-based solution provides agility and ability to scale quickly,” said Commonwealth’s President Geoff Gordon. “CVW combines valuable input from our early-adopter clients with innovative technology and insights from our development team to enhance the pharmacovigilance process as a whole, which in the end, can help save patients’ lives.”

With user-friendly dashboards that integrate data across various modules, the latest CVW enhancements improve:

  • Planning for safety data review,
  • Conducting signal detection, validation, and assessment,
  • Tracking signals, risks, and regulatory inquiries, and
  • Producing reports for internal and external stakeholder communication.

See Commonwealth Informatics’ website for more details.

About Commonwealth Informatics
Commonwealth Informatics is a technology and services company with industry expertise in medical product safety and public health surveillance. Pharmaceutical and biotechnology companies, government agencies, and healthcare providers use Commonwealth’s products and services to assemble relevant data and answer complex clinical and safety analysis questions quickly and accurately. Commonwealth is an independently-operated subsidiary of Genpact (NYSE: G), a global professional services firm focused on delivering digital transformation. Learn more about the innovative products and services that are helping to improve the speed and accuracy of pharmacovigilance evidence generation at https://www.commoninf.com.

CONTACT:
Michelle Tully
978-606-7682
mtully@commoninf.com 

View original content:http://www.prnewswire.com/news-releases/commonwealth-informatics-helps-life-science-companies-and-regulatory-agencies-improve-drug-safety-301251149.html

SOURCE Commonwealth Informatics, a Genpact company

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

46 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

47 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

4 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

5 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

19 hours ago